Nephrocan, pseudogene (NEPNP)

**Nephrocan, pseudogene (NEPNP)** is annotated as a pseudogene in humans and is related to the gene **nephrocan**, which encodes a secreted glycoprotein that acts as an inhibitor of the transforming growth factor-beta (TGF-β) signaling pathway[1][3]. Pseudogenes, by standard definition, resemble known coding genes but contain sequence defects (such as frameshifts or premature stop codons) that prevent the generation of a functional protein product[6]. Although nephrocan itself is a member of the small leucine-rich repeat protein family and has established biological function, the pseudogene version NEPNP is not believed to produce a functional protein and currently lacks evidence of coding potential or direct biological activity in human physiology[1][5][6]. **Key clarifications:** - NEPNP is annotated as a pseudogene, not a protein-coding gene or functional target. - There is no evidence to support NEPNP being a therapeutic target (e.g., receptor, enzyme, transporter, transcription factor), nor are there drugs or biomarkers associated with it. - The entry is "incorrect" as a drug discovery target or therapeutic receptor because pseudogenes are generally nonfunctional and not tractable for pharmacological intervention[6]. **Additional context:** - Nephrocan (the protein-coding parent gene, not the pseudogene) is a secreted regulator of TGF-β signaling and is part of the extracellular matrix. - NEPNP is only predicted to act upstream of or within extracellular matrix organization or transcriptional regulation by sequence homology, but not through proven protein function[5]. - Unless new research provides evidence for coding or regulatory function, NEPNP should not be considered a conventional drug target. If the intent was to retrieve information on the functional, protein-coding nephrocan gene, not its pseudogene, that would be a different entity with possible disease and signaling relevance[1][3][5][6].

Other names

NEPNPNPNNEPNnephrocan pseudogene